<DOC>
	<DOCNO>NCT02432716</DOCNO>
	<brief_summary>This study single center , randomize , double-blind , placebo-controlled , cross-over pilot study design ass safety intranasally ( IN ) deliver glulisine versus placebo patient DS . Subjects randomize cross-over study within subject comparison conduct single treatment intranasal insulin glulisine single treatment intranasal placebo . All subject also receive single treatment placebo prior randomization ensure adherence study procedure .</brief_summary>
	<brief_title>Investigation Safety Intranasal Glulisine Down Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Male female age 3580 year Down syndrome diagnosis confirm karyotype . Vital sign must within normal limit age . ( Medically treat hypertension allow ) . Must electrocardiogram free clinically significant finding . Must authorize representative provide write informed consent . Level speech comprehension verbal command sufficient understand answer simple request . Must reliable caregiver family member agree accompany subject visit , provide information subject require protocol . Must independent activity daily live . Must tolerate initial IN treatment placebo adhere study procedure . Any current psychiatric neurologic diagnosis Down syndrome Down syndrome dementia judge impact cognition . Subjects currently meet within past five year meet DSMIV ( Diagnostic Statistical Manual ) criteria drug alcohol abuse dependence . Subjects reside skilled nursing facility subject anticipate enter nursing home within next 6 month . ( Subjects may reside group home , assist living , residential setting require 24 hour skilled nursing . ) Subjects receive experimental drug Down syndrome within past 30 day screen visit . Subjects significant allergy significant intolerance insulin . Presence active seizure disorder . Presence significant aggression agitation may impact participation test IN administration . All subject must NPIC aggression agitation subscore ≤ 4 ( severity ≤ 2 ; frequency ≤ 2 ) . Significant cerebrovascular disease Modified Hachinski Score &gt; 4 . Subjects may able comply protocol perform outcomes measure due significant hear visual impairment issue judge relevant investigator . Subject diagnose form diabetes mellitus , actively take insulin , HbA1c &gt; 6.1 % screening .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>